ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome (MAESTRO-OL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01739400
Recruitment Status : Completed
First Posted : December 3, 2012
Last Update Posted : June 21, 2018
Sponsor:
Information provided by (Responsible Party):
Actelion

Brief Summary:
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: Macitentan 10 mg tablet, once daily. Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 217 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Actual Study Start Date : September 10, 2013
Actual Primary Completion Date : January 12, 2018
Actual Study Completion Date : January 12, 2018


Arm Intervention/treatment
Experimental: Macitentan
Macitentan 10 mg tablet, once daily.
Drug: Macitentan 10 mg tablet, once daily.
Macitentan 10 mg tablet, once daily.
Other Names:
  • Macitentan
  • ACT-064992




Primary Outcome Measures :
  1. (Serious) treatment-emergent adverse events (AEs) [ Time Frame: 3 years ]
    Treatment-emergent (serious) AEs up to 30 days after study drug discontinuation

  2. Treatment-emergent marked laboratory abnormalities (MLAs) [ Time Frame: up to EOT ]
    Treatment-emergent marked laboratory abnormalities (MLA) of interest up to EOT

  3. Proportion of subjects with treatment-emergent ALT and/or AST abnormality [ Time Frame: up to EOT ]
    Proportion of subjects with treatment-emergent ALT and/orAST abnormality (> 3 and ≤ 5 x ULN; > 5 and ≤ 8 x ULN;> 8 x ULN) associated or not with total bilirubin ≥ 2 x ULN, up to EOT.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects with ES (including those with Down Syndrome) having completed the double-blind AC-055-305 / MAESTRO study as scheduled, i.e., who remained in the double-blind study up to Week 16 (whether or not they were still taking study drug at the end of this period).

Exclusion Criteria:

Subjects who prematurely discontinue double-blind study drug during the AC-055-305 / MAESTRO study due to:

  • an AE assessed as related to the use of study drug,
  • or elevated liver tests (related or unrelated to study drug).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01739400


  Show 51 Study Locations
Sponsors and Collaborators
Actelion

Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT01739400     History of Changes
Other Study ID Numbers: AC-055-308
First Posted: December 3, 2012    Key Record Dates
Last Update Posted: June 21, 2018
Last Verified: June 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Actelion:
Eisenmenger Syndrome
exercise capacity

Additional relevant MeSH terms:
Hypertension
Familial Primary Pulmonary Hypertension
Eisenmenger Complex
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Heart Diseases
Congenital Abnormalities
Macitentan
Endothelin A Receptor Antagonists
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Endothelin B Receptor Antagonists